Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,300 peer-reviewed publications.

The CPRD bibliography is updated on a monthly basis (last updated 4 December 2019) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

(PDF, 3MB, 193 pages)

 

Export 70 results:
Author Title Type [ Year(Asc)]
Filters: Author is Leufkens, H. G.  [Clear All Filters]
2016
A. M. Gallagher, Williams, T., Leufkens, H. G., and de Vries, F., The Impact of the Choice of Data Source in Record Linkage Studies Estimating Mortality in Venous Thromboembolism, PLoS One, vol. 11, p. e0148349, 2016.
P. J. Peeters, Bazelier, M. T., Leufkens, H. G., Auvinen, A., van Staa, T. P., de Vries, F., and De Bruin, M. L., Insulin glargine use and breast cancer risk: Associations with cumulative exposure, Acta Oncol, vol. 55, pp. 851-8, 2016.
C. Klop, de Vries, F., Bijlsma, J. W., Leufkens, H. G., and Welsing, P. M., Predicting the 10-year risk of hip and major osteoporotic fracture in rheumatoid arthritis and in the general population: an independent validation and update of UK FRAX without bone mineral density, Ann Rheum Dis, vol. 75, pp. 2095-2100, 2016.
J. van Dalem, Brouwers, M. C., Stehouwer, C. D., Krings, A., Leufkens, H. G., Driessen, J. H., de Vries, F., and Burden, A. M., Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study, Bmj, vol. 354, p. i3625, 2016.
L. M. Knapen, van Dalem, J., Keulemans, Y. C., van Erp, N. P., Bazelier, M. T., De Bruin, M. L., Leufkens, H. G., Croes, S., Neef, C., de Vries, F., and Driessen, J. H., Use of incretin agents and risk of pancreatic cancer: a population-based cohort study, Diabetes Obes Metab, vol. 18, pp. 258-65, 2016.
2015
C. Klop, Gibson-Smith, D., Elders, P. J., Welsing, P. M., Leufkens, H. G., Harvey, N. C., Bijlsma, J. W., van Staa, T. P., and de Vries, F., Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000-2010, Osteoporos Int, vol. 26, pp. 1919-28, 2015.
J. H. Driessen, Henry, R. M., van Onzenoort, H. A., Lalmohamed, A., Burden, A. M., Prieto-Alhambra, D., Neef, C., Leufkens, H. G., and de Vries, F., Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis, Calcif Tissue Int, vol. 97, pp. 104-12, 2015.
H. A. van den Ham, Klungel, O. H., Singer, D. E., Leufkens, H. G., and van Staa, T. P., Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database, J Am Coll Cardiol, vol. 66, pp. 1851-9, 2015.
J. P. Yska, van Roon, E. N., de Boer, A., Leufkens, H. G., Wilffert, B., de Heide, L. J., de Vries, F., and Lalmohamed, A., Remission of Type 2 Diabetes Mellitus in Patients After Different Types of Bariatric Surgery: A Population-Based Cohort Study in the United Kingdom, JAMA Surg, vol. 150, pp. 1126-33, 2015.
P. J. Peeters, Bazelier, M. T., Leufkens, H. G., de Vries, F., and De Bruin, M. L., The risk of colorectal cancer in patients with type 2 diabetes: associations with treatment stage and obesity, Diabetes Care, vol. 38, pp. 495-502, 2015.
J. V. Been, Szatkowski, L., van Staa, T. P., Leufkens, H. G., van Schayck, O. C., Sheikh, A., de Vries, F., and Souverein, P., Smoke-free legislation and the incidence of paediatric respiratory infections and wheezing/asthma: interrupted time series analyses in the four UK nations, Sci Rep, vol. 5, p. 15246, 2015.
2014
V. Abbing-Karahagopian, Huerta, C., Souverein, P. C., de Abajo, F., Leufkens, H. G., Slattery, J., Alvarez, Y., Miret, M., Gil, M., Oliva, B., Hesse, U., Requena, G., de Vries, F., Rottenkolber, M., Schmiedl, S., Reynolds, R., Schlienger, R. G., de Groot, M. C., Klungel, O. H., van Staa, T. P., van Dijk, L., Egberts, A. C., Gardarsdottir, H., and De Bruin, M. L., Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications, Eur J Clin Pharmacol, vol. 70, pp. 849-57, 2014.
C. Klop, Welsing, P. M., Cooper, C., Harvey, N. C., Elders, P. J., Bijlsma, J. W., Leufkens, H. G., and de Vries, F., Mortality in British hip fracture patients, 2000-2010: a population-based retrospective cohort study, Bone, vol. 66, pp. 171-7, 2014.
S. Pouwels, de Boer, A., Leufkens, H. G., Weber, W. E., Cooper, C., and de Vries, F., Risk of fracture in patients with Charcot-Marie-Tooth disease, Muscle Nerve, vol. 50, pp. 919-24, 2014.
S. Pouwels, de Boer, A., Leufkens, H. G., Weber, W. E., Cooper, C., van Staa, T. P., and de Vries, F., Risk of fracture in patients with Guillain-Barre syndrome, Osteoporos Int, vol. 25, pp. 1845-51, 2014.
S. Pouwels, de Boer, A., Leufkens, H. G., Weber, W. E., Cooper, C., van Onzenoort, H. A., and de Vries, F., Risk of fracture in patients with muscular dystrophies, Osteoporos Int, vol. 25, pp. 509-18, 2014.
D. Gibson-Smith, Klop, C., Elders, P. J., Welsing, P. M., van Schoor, N., Leufkens, H. G., Harvey, N. C., van Staa, T. P., and de Vries, F., The risk of major and any (non-hip) fragility fracture after hip fracture in the United Kingdom: 2000-2010, Osteoporos Int, vol. 25, pp. 2555-63, 2014.
P. J. Peeters, Bazelier, M. T., Uitdehaag, B. M., Leufkens, H. G., De Bruin, M. L., and de Vries, F., The risk of venous thromboembolism in patients with multiple sclerosis: the Clinical Practice Research Datalink, J Thromb Haemost, vol. 12, pp. 444-51, 2014.
J. H. Driessen, van Onzenoort, H. A., Henry, R. M., Lalmohamed, A., van den Bergh, J. P., Neef, C., Leufkens, H. G., and de Vries, F., Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture, Bone, vol. 68, pp. 124-30, 2014.
2008
E. Setakis, Leufkens, H. G., and van Staa, T. P., Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib, Arthritis Rheum, vol. 59, pp. 1105-11, 2008.
T. P. van Staa, Rietbrock, S., Setakis, E., and Leufkens, H. G., Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?, J Intern Med, vol. 264, pp. 481-92, 2008.
T. P. van Staa, Smeeth, L., Persson, I., Parkinson, J., and Leufkens, H. G., Evaluating drug toxicity signals: is a hierarchical classification of evidence useful or a hindrance?, Pharmacoepidemiol Drug Saf, vol. 17, pp. 475-84, 2008.
T. P. van Staa, Cooper, C., Barlow, D., and Leufkens, H. G., Individualizing the risks and benefits of postmenopausal hormone therapy, Menopause, vol. 15, pp. 374-81, 2008.
M. J. Willemen, Mantel-Teeuwisse, A. K., Straus, S. M., Leufkens, H. G., and Egberts, A. C., Psychiatric and cardiovascular comorbidities in patients with diabetes mellitus starting antiobesity drugs, Obesity (Silver Spring), vol. 16, pp. 2331-5, 2008.
T. P. van Staa, Smeeth, L., Persson, I., Parkinson, J., and Leufkens, H. G., What is the harm-benefit ratio of Cox-2 inhibitors?, Int J Epidemiol, vol. 37, pp. 405-13, 2008.
[Page last reviewed 6 December 2019]